![Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes - ScienceDirect Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109717397619-fx1.jpg)
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes - ScienceDirect
![Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial - The Lancet Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/c2014e18-7e6b-4b55-a38c-4b8e60813f28/gr1.gif)
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial - The Lancet
![Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial | JACC: Heart Failure Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial | JACC: Heart Failure](https://www.jacc.org/cms/asset/63928e3f-fb9a-4560-a48e-d12aa19a9e01/gr2.jpg)
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial | JACC: Heart Failure
![Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213177921005837-fx1.jpg)
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial - ScienceDirect
![PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF | MDedge Cardiology PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF | MDedge Cardiology](https://cdn.mdedge.com/files/s3fs-public/Kosiborod_Mikhail_N_2021_web.jpg)
PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF | MDedge Cardiology
![Pharmacoepidemiology | Free Full-Text | Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure Pharmacoepidemiology | Free Full-Text | Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure](https://www.mdpi.com/pharmacoepidemiology/pharmacoepidemiology-01-00009/article_deploy/html/images/pharmacoepidemiology-01-00009-g001.png)
Pharmacoepidemiology | Free Full-Text | Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure
![A) Diagnosis of heart failure with preserved ejection fraction. (B)... | Download Scientific Diagram A) Diagnosis of heart failure with preserved ejection fraction. (B)... | Download Scientific Diagram](https://www.researchgate.net/publication/334122588/figure/fig1/AS:775531167485952@1561912447736/A-Diagnosis-of-heart-failure-with-preserved-ejection-fraction-B-Grading-of-diastolic.png)
A) Diagnosis of heart failure with preserved ejection fraction. (B)... | Download Scientific Diagram
![The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01536-x/MediaObjects/41591_2021_1536_Fig2_HTML.png)
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial | Nature Medicine
![Approach to diagnosis of heart failure with preserved ejection fraction... | Download Scientific Diagram Approach to diagnosis of heart failure with preserved ejection fraction... | Download Scientific Diagram](https://www.researchgate.net/publication/341883116/figure/fig2/AS:898451462180865@1591218929544/Approach-to-diagnosis-of-heart-failure-with-preserved-ejection-fraction-HFpEF-LVEF.png)
Approach to diagnosis of heart failure with preserved ejection fraction... | Download Scientific Diagram
![Sanjiv J. Shah, MD on Twitter: "PRESERVED-HF is now published and online @NatureMedicine. RCT of #SGLT2i vs placebo in n=324 #HFpEF pts, LVEF>45%. Clearly positive trial with no heterogeneity by LVEF. +5.8 Sanjiv J. Shah, MD on Twitter: "PRESERVED-HF is now published and online @NatureMedicine. RCT of #SGLT2i vs placebo in n=324 #HFpEF pts, LVEF>45%. Clearly positive trial with no heterogeneity by LVEF. +5.8](https://pbs.twimg.com/media/FCzEoAlXEAQcuUb.jpg)
Sanjiv J. Shah, MD on Twitter: "PRESERVED-HF is now published and online @NatureMedicine. RCT of #SGLT2i vs placebo in n=324 #HFpEF pts, LVEF>45%. Clearly positive trial with no heterogeneity by LVEF. +5.8
![JCM | Free Full-Text | Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain JCM | Free Full-Text | Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain](https://www.mdpi.com/jcm/jcm-11-05199/article_deploy/html/images/jcm-11-05199-g001.png)
JCM | Free Full-Text | Prevalence, Characteristics, Management and Outcomes of Patients with Heart Failure with Preserved, Mildly Reduced, and Reduced Ejection Fraction in Spain
![EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT EMPEROR-Preserved: Empagliflozin in heart failure with preserved or mildly-reduced ejection fraction — NERDCAT](http://static1.squarespace.com/static/56a0651bbe7b96af3e170173/t/6140e3eb4c5b1479277e7891/1631644751499/emperor-preserved+efficacy.png?format=1500w)